Jennifer K. Litton
Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.
Breast medical oncologist who was principal investigator of EMBRACA and of neoadjuvant talazoparib studies in germline BRCA carriers. Oversees clinical research operations across MD Anderson.
| Title | Journal | Year |
|---|---|---|
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | New England Journal of Medicine | 2018 |
| Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant | Journal of Clinical Oncology | 2020 |
Pages like this
not linked directly; found by shared links- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares PARP inhibitors, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- TrialPOLO
Shares PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- ProductIniparib
Shares Talazoparib, PARP inhibitors, PARP, Triple-negative breast cancer (TNBC).
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonAlan Ashworth
Shares PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- TrialTALAPRO-2
Shares Talazoparib, PARP, BRCA1 / BRCA2 (HRD).
- PersonMariana Chavez-MacGregor
Shares MD Anderson Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonSusan M. Domchek
Shares PARP, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).